Lenvatinib vs. Sorafenib (HCC)
from OncoPharm Hosted by John Bossaer
Reviewing the REFLECT (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30207-1/fulltext) study and its take-home points on selecting an agent for advanced HCC.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 11 minutes long.
When was this OncoPharm episode published?
This episode was published on April 24, 2019.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.